The Microcyn^® Technology platform was first introduced in Mexico in 2003. The Mexican Ministry of Health approved Microcyn^® as a disinfectant and antiseptic in July of that same year, and then as a sterilant in November.

Many key medical opinion leaders in Mexico and Europe have tested and validated the Microcyn^® Technology’s efficacy and safety. It has received CE mark approval in Europe for treatment of acute and chronic wounds as well as two United States FDA 510K clearances to moisten, lubricate, cleanse and debride wounds and burns.

Microcyn^® Technology is initially being used in the treatment of complex wounds, such as burns and diabetic foot ulcers, in which infection can pose significant danger to the patient. While in-vitro studies have shown that Microcyn^® can effectively eradicate bacteria, numerous in-vivo studies have also confirmed the same bacteria-eradicating results in open wounds. In numerous third-party case studies conducted to date by individual physicians, the use of both systemic and dermal antibiotics has been significantly reduced when Microcyn^® Technology was used. The results of a 64-patient study in burn patients were presented at the Texas Surgical Society in April 2005.

Diabetic Foot Ulcers

Diabetic foot ulcers treated with Microcyn^® Technology as part of a comprehensive treatment regimen have shown both elimination of the fetid odor as well as clinical benefits with respect to the reduction of cellulitis and tissue toxicity. Patients that in the past might have had to undergo radical procedures such as amputation, are now being healed and their limbs saved. The Microcyn^® Technology has been used in Mexico, Europe and India on thousands of patients for treatment of diabetic ulcers with excellent results. Diabetic ulcers are considered a complex wound in which many factors can influence or delay wound healing. These factors include, but are not limited to, vascular health, insulin levels and dietary controls among others. In all cases, the comprehensive regimen with Microcyn^® Technology has shown to effectively eradicate both infection and the fetid odor, while facilitating enhanced wound healing.

Burns

Second- and third-degree burns are very challenging due to the high risk of infection since the skin is no longer a barrier to infection. As well, skin grafts offer potential for a number of complications. A graft "takes" or is successful when new blood vessels and tissue form in the injured area. Sometimes, skin grafts do not take because of early complications such as infection, which is the most common cause of graft failure. Based upon the results from a clinical study conducted at the Guadalajara Civil
Hospital, when patients are treated with Microcyn^® Technology in a comprehensive treatment program, healing of the burns is accelerated, the levels of pain and infection reduced and the patient hospital stay is significantly reduced.

Varicose Vein Leg Ulcers

Stasis ulcers oftentimes present a devastating lifestyle. The pain is constant and the odor horrific. These patients live with both the pain and decaying stench 24 hours a day, seven days a week—many for the greater part of their lives. The degree of ulceration is oftentimes exacerbated by a general neglect of the wound that can be the result of limited access to modern medical care.

Compounding this is the fact that invading bacteria can grow resistant in reaction to antibiotics that are used to treat the ulcer. Conventional antiseptics provide some relief against most bacteria. However, many antiseptics can actually induce damage to the healthy tissue surrounding these ulcers. It is a real dilemma since what is typically used in an attempt to prevent infection may end up causing even greater harm to the patient.

Within a few weeks after first treating patients with the Microcyn^® Technology regimen, physicians begin to see healing in decades-old ulcers that was previously unheard of. The photos below graphically illustrate the significant results achieved on these ulcers when treated with a Microcyn^® Technology-based regimen.

NOTE: Microcyn® does not have U.S. FDA clearance for claims other than to moisten, lubricate, cleanse and debride wounds.